Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Scientists have developed an artificial intelligence system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack.
In a preliminary study, Johns Hopkins Medicine researchers report that as many as a third of those with "wet" age-related macular degeneration may someday be able to safely stop eye injection therapy without further vision loss.
Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA).
Using a stem-cell-derived model, researchers have identified two drug candidates that may slow dry age-related macular degeneration (AMD), a leading cause of blindness for which no treatment exists.
Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease.
Researchers from UCSB report the development of a new microscope they describe as “Dual Independent Enhanced Scan Engines for Large field-of-view Two-Photon imaging (Diesel2p),” which provides unprecedented brain-imaging ability.
CellSight researchers at the University of Colorado School of Medicine are offering the first evidence connecting drusen formation, or yellowish deposits that accumulate under the retina, with extracellular vesicles and age-related macular degeneration.
Researchers have uncovered the mechanism of vision loss in Usher syndrome, yielding additional drug targets for eventual development of better therapies.
The Medical College of Georgia scientists have early evidence that HBI-002, a low-dose oral compound, can safely reduce oxidative stress and inflammation in the retina, both early, major contributors to diabetic retinopathy.
An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.
